You are here: Industry Insights > Samsung Bioepis

News List

Samsung Bioepis gets nod for sale of biosimilar drug in Europe firstwordpharma
March 06, 2019
Samsung Bioepis has won European approval of a 420-mg dosage of Ontruzant, a biosimilar of Roche's Herceptin, The Korea Herald reported Tuesday.
Samsung Bioepis forms new alliance to expand in China pharmaceutical-technology
February 13, 2019
Samsung Bioepis has signed a licensing deal with healthcare-focused private equity firm C-Bridge Capital to accelerate expansion in mainland China....
Samsung Bioepis secures FDA approval for cancer drug Ontruzant pharmaceutical-technology
January 22, 2019
The US Food and Drug Administration (FDA) has granted approval for Samsung Bioepis to use Ontruzant (trastuzumab-dttb) to treat a range of cancers.....
Samsung Bioepis to Initiate Phase 1 Clinical Trial of SB26 americanpharmaceuticalreview
August 14, 2018
Samsung Bioepis will soon begin a Phase 1 study to evaluate SB26 in healthy volunteers. SB26, also known as TAK-671, is an ulinastatin-Fc (UTI-Fc) fusion protein intended to treat severe acute pancreatitis. Non-clinical GLP safety studies performed in mon
Biogen, Samsung Bioepis and Abbvie settle patent dispute pharmatimes
July 18, 2018
Biogen and Samsung Bioepis have laid to rest a long-running patent wrangle with AbbVie regarding a biosimilar form of the latter’s blockbuster Humira.
Samsung wins first CHMP backing for a Herceptin biosim, imperiling $2B in Roche sales fiercepharma
September 18, 2017
As challengers to Roche’s cancer blockbusters advance in the U.S. and around the world, Samsung Bioepis has taken a big step toward approval for a Herceptin biosim in Europe.
Samsung-Takeda R&D pact, GSK-Alibaba vaccine union, Gland’s renewed M&A deal fiercepharma
August 28, 2017
With a newly formed drug co-development deal, Samsung Bioepis is finally moving into novel drug R&D.
Samsung Bioepis, Takeda Sign Agreement to Co-Develop Multiple Novel Biologic Therapies americanpharmaceuticalreview
August 22, 2017
Samsung Bioepis has entered into a strategic collaboration agreement with Takeda to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas.

Previous page 1 2 Next page